Saturday, October 3, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleSeeking Alpha· February 20, 2026

F&G signals shift toward 25% fee-based earnings by 2028 while expanding AUM and capital flexibility

View original at seekingalpha.com
F&G signals shift toward 25% fee-based earnings by 2028 while expanding AUM and capital flexibility Earnings Call Insights: F&G Annuities & Life, Inc…
Opening lines of the source · Seeking Alpha · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • FNF distribution strengthens F&G's positioning within equity markets and facilitates greater institutional ownership

    80% confidence
  • F&G feels comfortable and confident in the credit soundness of the investment portfolio

    80% confidence
  • Starting Q1 2026, F&G is updating long-term expected return for alternative investments to reflect only 40% or $4 billion of equity interest, with no impact to adjusted net earnings on an as-reported basis

    80% confidence
  • F&G plans for continued mediocre returns as the prudent approach

    80% confidence
  • F&G has a blended return of approximately 10% on current basis, with quarterly return in the 7% to 7.5% range

    80% confidence
  • Operating expense ratio expected to improve to approximately 45 basis points by year-end 2027 for a cumulative 15 basis points or 25% improvement over the 3-year period

    80% confidence
  • The Ancient Financial Holdings transaction offers counterparty diversification for MYGA flow reinsurance in the future

    80% confidence
  • F&G is trading at $0.62 of book value and the stock is trading as though there are billions of credit losses coming

    80% confidence
  • Fee-based earnings are expected to reach approximately 25% of total earnings by year-end 2028

    80% confidence
  • $200 million of the $300 million proceeds have already been included in RBC number at year-end, with another $100 million to come for general uses including sales growth and AUM growth

    80% confidence
  • F&G delivered a strong finish to an outstanding year through disciplined growth and proven business model flexibility, transitioning to be more fee-based, higher margin and less capital intensive

    80% confidence
  • Annuity terminations are a potential source of quarterly variability as F&G moves into 2026

    80% confidence
  • If surrenders come down when F&G has more assets, the company would rather have the assets even if it meant less expansion of ROA

    80% confidence
  • Software exposure is less than 5% of the total portfolio, with less than 1% having disruption risk

    80% confidence
  • F&G will continue to write MYGA but will be more selective about it due to significant fluctuation in demand

    80% confidence
  • F&G expects to receive net proceeds of approximately $300 million from the sale of F&G Life Re Limited legal entity and runoff in-force block

    80% confidence
  • F&G will pull fixed costs down a few percent to fund variable costs while continuing to grow without growing expenses

    80% confidence
  • F&G feels very confident in what's in the investment portfolio

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com